Please find attached press release for the quarter and financial year ended March 31, 2026.
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.9 pts more than Nifty Microcap 250 and 10.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Procter & Gamble Health Ltd reported strong Q4 FY26 results with sales of ₹365 crores, up 20% year-over-year, and PAT of ₹95 crores, up 55%. For the full year ending March 2026, the company achieved sales of ₹1,385 crores (up 16%) and PAT of ₹327 crores (up 30%) compared to the comparable 12-month period last year. The company noted it changed its fiscal year from July-June to April-March, making results comparable to the April 2024-March 2025 period. Management highlighted investment in product innovations including Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream. The board recommended a final dividend of ₹45 per share, taking total dividend payout to ₹205 per share including the interim dividend already paid.
Strong double-digit revenue and profit growth with robust PAT expansion signals operational efficiency gains. The increased dividend payout is positive for income-focused shareholders, and the new product launches indicate continued focus on portfolio expansion.